` TVGN (Tevogen Bio Holdings Inc) vs S&P 500 Comparison - Alpha Spread

TVGN
vs
S&P 500

Over the past 12 months, TVGN has significantly outperformed S&P 500, delivering a return of 50% compared to the S&P 500's 10% growth.

Stocks Performance
TVGN vs S&P 500

Loading

Performance Gap
TVGN vs S&P 500

Loading
TVGN
S&P 500
Difference

Performance By Year
TVGN vs S&P 500

Loading
TVGN
S&P 500
Add Stock

Competitors Performance
Tevogen Bio Holdings Inc vs Peers

S&P 500
TVGN
ABBV
AMGN
GILD
VRTX
Add Stock

Tevogen Bio Holdings Inc
Glance View

Market Cap
226.2m USD
Industry
Biotechnology

Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The firm is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

TVGN Intrinsic Value
Not Available
T
Back to Top